Last 47 quarters of trend data · Healthcare · Drug Manufacturers - General
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 120.21 | 30.84 | 139.42 | 56.00 | 582.93 | 87.56 | 72.75 | — | 56.10 | 55.69 | 59.12 | 84.22 | 37.27 | 29.55 | 306.48 | 29.07 | 15.11 | 75.08 | 16.02 | 14.98 | 15.15 |
| — | -64.8% | +91.6% | — | +939.0% | +57.2% | +23.0% | — | +50.5% | +88.5% | -80.7% | +189.8% | +146.6% | -60.6% | +1813.3% | +94.1% | -0.2% | +12.0% | +17.8% | -99.4% | -10.7% | |
| P/S Ratio | 8.23 | 6.56 | 6.43 | 6.10 | 6.50 | 5.33 | 6.96 | 5.22 | 6.05 | 5.25 | 6.56 | 4.80 | 4.74 | 4.30 | 5.79 | 4.75 | 4.02 | 4.66 | 5.32 | 4.04 | 3.34 |
| — | +23.0% | -7.6% | +16.9% | +7.5% | +1.5% | +6.1% | +8.6% | +27.7% | +22.1% | +13.3% | +1.0% | +17.8% | -7.7% | +8.7% | +17.5% | +20.4% | +30.2% | +44.2% | +17.4% | +11.0% | |
| P/B Ratio | — | — | — | — | — | — | 253.95 | 93.66 | 57.64 | 44.53 | 40.12 | 26.41 | 21.76 | 18.50 | 21.28 | 16.62 | 14.87 | 18.52 | 17.67 | 15.60 | 14.12 |
| — | — | — | — | — | — | +532.9% | +254.6% | +164.8% | +140.7% | +88.6% | +58.9% | +46.3% | -0.1% | +20.4% | +6.6% | +5.3% | +16.6% | +26.3% | +7.0% | +38.9% | |
| P/FCF | 28.25 | 30.10 | 27.06 | 20.73 | 13.63 | 16.84 | 66.30 | 11.66 | 16.83 | 37.41 | 20.98 | 15.09 | 8.97 | 9.71 | 17.61 | 9.96 | 8.03 | 13.99 | 15.18 | 12.31 | 6.21 |
| — | +78.8% | -59.2% | +77.8% | -19.0% | -55.0% | +216.0% | -22.8% | +87.6% | +285.1% | +19.1% | +51.6% | +11.8% | -30.6% | +16.0% | -19.1% | +29.3% | +31.3% | +48.2% | +18.1% | -10.3% | |
| EV / EBITDA | 20.09 | 15.23 | 16.84 | 15.04 | 29.83 | 14.15 | 18.88 | 154.16 | 17.50 | 14.74 | 19.44 | 15.27 | 17.24 | 10.74 | 17.28 | 11.17 | 10.87 | 15.73 | 13.13 | 10.94 | 10.11 |
| — | +7.7% | -10.8% | -90.2% | +70.5% | -4.0% | -2.8% | +909.7% | +1.5% | +37.3% | +12.5% | +36.6% | +58.5% | -31.7% | +31.6% | +2.2% | +7.5% | +52.7% | +23.9% | -5.5% | -4.3% | |
| EV / EBIT | 28.23 | 18.96 | 63.97 | 34.67 | 81.45 | 42.82 | 46.17 | — | 36.89 | 31.45 | 39.21 | 45.31 | 31.05 | 23.00 | 82.30 | 24.24 | 14.93 | 48.36 | 16.23 | 15.90 | 15.19 |
| — | -55.7% | +38.6% | — | +120.8% | +36.2% | +17.7% | — | +18.8% | +36.7% | -52.4% | +87.0% | +108.0% | -52.5% | +407.0% | +52.4% | -1.7% | +25.7% | +9.1% | — | -18.9% |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 70.2% | 74.7% | 71.9% | 72.6% | 66.4% | 71.8% | 70.0% | 70.9% | 70.9% | 70.9% | 66.7% | 60.1% | 53.4% | 69.4% | 67.4% | 72.4% | 66.1% | 71.4% | 70.1% | 71.0% | 69.4% |
| — | +4.1% | +2.7% | +2.4% | -6.3% | +1.2% | +4.9% | +17.9% | +32.6% | +2.2% | -1.0% | -17.0% | -19.2% | -2.8% | -3.8% | +2.0% | -4.7% | +5.6% | +3.6% | +7.2% | +14.0% | |
| Operating Margin | 32.8% | 37.9% | 31.6% | 35.0% | 12.1% | 31.7% | 28.0% | -9.9% | 26.5% | 27.6% | 22.7% | 22.3% | 16.4% | 32.5% | 22.6% | 36.4% | 31.1% | 22.6% | 34.8% | 34.1% | 30.0% |
| — | +19.3% | +12.8% | +454.3% | -54.4% | +14.8% | +23.1% | -144.2% | +61.8% | -15.1% | +0.4% | -38.6% | -47.3% | +44.1% | -35.0% | +6.8% | +3.5% | -29.0% | +10.5% | +25.9% | +19.0% | |
| Net Margin | 6.9% | 21.3% | 4.7% | 10.9% | 1.2% | 6.1% | 9.6% | -0.1% | 10.8% | 9.5% | 11.1% | 5.7% | 12.8% | 14.6% | 2.0% | 16.4% | 26.7% | 6.3% | 33.2% | 27.2% | 22.2% |
| — | +249.7% | -51.7% | +7600.3% | -89.1% | -35.8% | -13.3% | -102.5% | -15.4% | -35.1% | +468.8% | -64.9% | -52.1% | +130.4% | -94.1% | -39.8% | +20.3% | +15.5% | +21.4% | +10356.7% | +23.9% |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 6214.7% | — | — | — | — | 141.7% | 53.3% | -0.5% | 24.2% | 18.4% | 14.8% | 7.3% | 14.2% | 15.4% | 1.6% | 14.8% | 25.7% | 6.0% | 28.3% | 27.9% | 24.3% |
| — | — | — | — | — | +668.9% | +259.0% | -106.4% | +70.4% | +19.3% | +850.0% | -50.8% | -44.7% | +159.2% | -94.5% | -46.7% | +5.8% | +2.4% | +6.8% | +10892.6% | +58.0% | |
| ROA | 3.1% | 2.7% | 0.5% | 1.4% | 0.1% | 0.7% | 0.9% | -0.0% | 1.1% | 0.9% | 1.0% | 0.6% | 1.3% | 1.5% | 0.2% | 1.8% | 2.8% | 0.6% | 3.1% | 2.7% | 2.1% |
| — | +287.7% | -45.5% | +8681.6% | -87.5% | -27.2% | -1.8% | -102.6% | -16.4% | -37.2% | +452.0% | -65.6% | -52.8% | +132.4% | -94.4% | -35.5% | +29.6% | +25.7% | +31.3% | +11308.8% | +38.8% | |
| ROIC | 23.9% | 8.4% | 6.1% | 7.2% | 2.3% | 5.6% | 4.2% | -1.6% | 4.3% | 4.7% | 3.4% | 4.1% | 2.7% | 5.1% | 2.9% | 5.6% | 4.5% | 3.0% | 4.2% | 4.6% | 3.8% |
| — | +48.3% | +42.6% | +537.1% | -46.4% | +20.8% | +23.1% | -140.3% | +56.1% | -7.6% | +17.1% | -27.7% | -39.3% | +66.6% | -30.5% | +22.8% | +17.7% | -19.9% | +24.8% | +52.2% | +49.8% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | — | 47.80 | 20.17 | 11.71 | 10.36 | 9.20 | 5.78 | 5.01 | 4.73 | 4.67 | 3.71 | 4.34 | 4.97 | 4.50 | 5.03 | 5.95 |
| — | — | — | — | — | — | +419.8% | +248.8% | +133.8% | +118.9% | +97.0% | +55.7% | +15.3% | -4.7% | +3.6% | -26.1% | -27.0% | -23.9% | -27.7% | -24.4% | +4.4% | |
| Debt / EBITDA | 2.45 | 8.46 | 10.92 | 8.83 | 17.33 | 10.15 | 12.11 | 110.85 | 12.03 | 11.52 | 15.19 | 11.41 | 13.45 | 9.01 | 12.68 | 8.38 | 10.22 | 13.64 | 10.85 | 11.00 | 12.55 |
| — | -16.6% | -9.8% | -92.0% | +44.1% | -11.9% | -20.3% | +871.9% | -10.6% | +27.9% | +19.7% | +36.1% | +31.6% | -34.0% | +16.9% | -23.8% | -18.5% | +10.3% | -19.8% | -26.5% | -20.1% | |
| Current Ratio | 0.67 | 0.81 | 0.80 | 0.67 | 0.72 | 0.74 | 0.76 | 0.66 | 0.65 | 0.81 | 0.94 | 0.87 | 0.96 | 0.89 | 0.96 | 0.96 | 0.93 | 0.84 | 0.82 | 0.79 | 1.01 |
| — | +9.9% | +4.8% | +1.7% | +12.3% | -8.8% | -18.8% | -24.3% | -32.5% | -9.9% | -2.5% | -9.5% | +2.9% | +6.0% | +17.8% | +21.4% | -8.5% | -6.9% | -2.0% | -5.9% | +6.7% | |
| Quick Ratio | 0.56 | 0.69 | 0.68 | 0.56 | 0.60 | 0.61 | 0.64 | 0.55 | 0.54 | 0.71 | 0.83 | 0.76 | 0.84 | 0.77 | 0.82 | 0.84 | 0.83 | 0.75 | 0.71 | 0.70 | 0.91 |
| — | +12.2% | +6.4% | +0.8% | +10.6% | -13.5% | -23.7% | -27.7% | -35.6% | -8.2% | +1.6% | -9.3% | +1.2% | +3.2% | +16.0% | +19.6% | -8.3% | -5.4% | -2.9% | -3.2% | +12.2% | |
| Interest Coverage | 3.28 | 9.01 | 2.45 | 4.74 | 1.97 | 3.10 | 3.37 | -2.23 | 3.89 | 3.96 | 3.66 | 3.15 | 4.52 | 5.73 | 1.86 | 6.24 | 8.86 | 3.13 | 9.99 | 8.36 | 7.19 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 47 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
Bull/bear thesis, analyst target revisions, and earnings execution.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying ABBV stock.
AbbVie Inc.'s current P/E is 120.2x. The average P/E over the last 4 quarters is 202.3x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
AbbVie Inc.'s current operating margin is 32.8%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking AbbVie Inc.'s business trajectory between earnings reports.